Decitabine Can Be Safely Reduced after Achievement of Best Objective Response in Patients with Myelodysplastic Syndrome

Decitabine is standard therapy in patients with myelodysplastic syndrome (MDS). Current recommendations suggest a dose of 20 mg/m(2) IV daily for 5 days every 4 weeks. However, this therapy is associated with frequent grade 3–4 hematologic toxicity, requiring dose reductions (DR) and/or dose delays...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Ghanem, Hady, Cornelison, A. Megan, Garcia-Manero, Guillermo, Kantarjian, Hagop, Ravandi, Farhad, Kadia, Tapan, Cortes, Jorge, O’Brien, Susan, Brandt, Mark, Borthakur, Gautam, Jabbour, Elias
Format: Artigo
Idioma:Inglês
Publicat: 2013
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4120258/
https://ncbi.nlm.nih.gov/pubmed/23969308
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clml.2013.05.025
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars